Emerging therapeutics for the treatment of diabetic nephropathy

Jehrod Brenneman; Jon Hill; Steve Pullen

doi:10.1016/j.bmcl.2016.07.079

Emerging therapeutics for the treatment of diabetic nephropathy

Bioorg Med Chem Lett. 2016 Sep 15;26(18):4394-4402. doi: 10.1016/j.bmcl.2016.07.079. Epub 2016 Aug 1.

Authors

Jehrod Brenneman¹, Jon Hill², Steve Pullen³

Affiliations

¹ Small Molecule Discovery Research, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA. Electronic address: jehrod.brenneman@boehringer-ingelheim.com.
² Research Networking, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA.
³ Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA.

PMID: 27520943
DOI: 10.1016/j.bmcl.2016.07.079

Abstract

Diabetic nephropathy (DN) is the most common pathology contributing to the development of chronic kidney disease (CKD). DN caused by hypertension and unmitigated inflammation in diabetics, renders the kidneys unable to perform normally, and leads to renal fibrosis and organ failure. The increasing global prevalence of DN has been directly attributed to rising incidences of Type II diabetes, and is now the largest non-communicable cause of death worldwide. Despite the high morbidity, successful new treatments for DN are lacking. This review seeks to provide new insight on emerging clinical candidates under investigation for the treatment of DN.

Keywords: Diabetic nephropathy; Fibrosis; Inflammation; Kidney disease; Therapeutics.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2 / complications
Diabetic Nephropathies / complications
Diabetic Nephropathies / drug therapy*
Humans